Avid Bioservices Inc (CDMO)

[The Other Guy]

Sound familiar???

"The stock analyst, David Nierengarten, with Los Angeles-based Wedbush Securities, said the columnist's July 10 article, packed with medical and scientific language, was "factually incorrect" on one point. Nierengarten said he also does not think it's ethical for the journalist to repeat an investor's predictions of failure for the GTx drug trials when that investor gains from stock-price declines with an investment strategy known as "shorting the stock."

"I don't have a problem with people shorting the stock," he said. "I have a problem with people using journalists to manipulate a stock."

TheStreet's columnist, Adam Feuerstein, said that his article wasn't in error, but looked at things in a different way than Nierengarten, who criticized the column after it appeared.

Feuerstein, in Boston, said he's paid to analyze and provide opinions about biotechnology companies and their drugs. Working with the investor he didn't name -- whom he said is a Harvard-trained medical doctor and fund manager who has been right about drug trials before -- he concluded that GTx's drug won't measure up.

"When it comes to biotechnology, there are people who believe in these companies and these drugs and there are people who don't," Feuerstein said. "You make money both ways

http://medcitynews.com/2013/07/analyst-unethical-twitter-chatter-by-thestreet-leads-to-shorting-of-memphis-biotech-firms-stock/#ixzz2ZyR1XM5O

AF should be in jail...